PharmAthene, a biodefence company, has appointed Charles Reinhart III to the position of senior vice president (SVP), chief financial officer (CFO), with responsibility for overseeing the company’s accounting and finance functions, human resources and information technology. Christopher Camut, who held the position of vice president and CFO since January 2007, has been appointed to the newly created position of vice president, government contracting and special projects.
Prior to joining PharmAthene, Reinhart served as SVP finance and corporate strategy, and was a member of the operating leadership team of Millennium Pharmaceuticals, where he was responsible for all aspects of the company’s finance and strategic sourcing functions.
Previously, Reinhart was vice president of finance at Cephalon, where he was responsible for worldwide accounting, financial reporting, Sarbanes Oxley (SOX) compliance, tax, treasury and budgeting/forecasting functions, and was a key member of the team responsible for raising over US$2.6bn in convertible debt transactions.
Reinhart is a certified public accountant (CPA). He earned his MBA from The Wharton School at the University of Pennsylvania and his undergraduate degree in Business and Economics from Lehigh University. He currently serves as a member of the board of directors of VectorLogics.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.